Abstract
Purpose
Metronomic combination chemotherapy with the oral fluoropyrimidine doxifluridine/5′-deoxy-5-fluorouridine (5 -DFUR) and oral cyclophosphamide (C) showed promising efficacy in a single-arm study. The oral fluoropyrimidine capecitabine was designed to deliver 5-fluorouracil preferentially to tumors, potentially improving efficacy over doxifluridine. We conducted a phase II multicenter study to evaluate an all-oral XC combination in patients with HER2-negative metastatic breast cancer (MBC).
Materials and methods
Patients received capecitabine 828 mg/m2 twice daily with cyclophosphamide 33 mg/m2 twice daily, days 1–14 every 3 weeks. The primary endpoint was overall response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety.
Results
Between May 2007 and April 2009, 51 patients were enrolled and 45 were included in the efficacy analysis. The median follow-up was 18.1 months. ORR was 44.4% and stable disease (≥24 weeks) was achieved in 13.4%, resulting in a 57.8% clinical benefit response rate. Median PFS was 12.3 months (95% confidence interval: 8.9–18.9 months). Median PFS was 10.7 months in triple-negative disease and 13.2 months in estrogen-receptor positive, HER2-negative disease. The 1- and 2-year OS rates were 86 and 71%, respectively. Median OS has not been reached. Grade 3 adverse events comprised leukopenia (26%), neutropenia (16%), and decreased hemoglobin (2%). There was no grade 3 hand-foot syndrome.
Conclusions
Oral XC is an effective first- or second-line therapy for MBC, demonstrating high activity in both luminal A and triple-negative disease with few severe side effects. This metronomic oral combination chemotherapy could be beneficial for the treatment of HER2-negative MBC.
References
Early Breast Cancer Trialist Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717
Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP (2008) Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst 100:1780–1791
Rahman ZU, Frye DK, Smith TL, Asmar L, Theriault RL, Buzdar AU, Hortobagyi GN (1999) Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference. Cancer 85:104–111
Hortobagyi GN (2002) Can we cure limited metastatic breast cancer? J Clin Oncol 20:620–623
Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, Pruneri G, Agliano A, Goldhirsch A, Shaked Y, Kerbel RS, Bertolini F (2006) Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108:452–459
Pasquier E, Kavallaris M, André N (2010) Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 7:455–465
Kamen BA, Rubin E, Aisner J, Glatstein E (2000) High-time chemotherapy or high time for low dose. J Clin Oncol 18:2935–2937
Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105:1045–1047
Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O’Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878–1886
Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K, Usuki K, Takaku F, Risau W, Heldin CH (1989) Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 338:557–562
Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4:1013–1019
Endo M, Shinbori N, Fukase Y, Sawada N, Ishikawa T, Ishitsuka H, Tanaka Y (1999) Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 83:127–134
O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812–2823
Blum JL, Dees EC, Chacko A, Doane L, Ethirajan S, Hopkins J, McMahon R, Merten S, Negron A, Neubauer M, Ilegbodu D, Boehm KA, Asmar L, O’Shaughnessy JA (2006) Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 24:4384–4390
Endo M, Fujimoto-Ouchi K, Matsumoto T, Tanaka Y, Ishitsuka H (1997) Efficacy of combination chemotherapy of cyclophosphamide and 5′-deoxy-5-fluorouridine in a mammary tumor xenograft model, MX-1. Jpn J Cancer Chemother 24:1295–1301
Yoshimoto M, Tada K, Tokudome N, Kutomi G, Tanabe M, Goto T, Nishimura S, Makita M, Kasumi F (2003) The potential for oral combination chemotherapy of 5′-deoxy-5-fluorouridine, a 5-FU prodrug, and cyclophosphamide for metastatic breast cancer. Br J Cancer 89:1627–1632
Ebi H, Sigeoka Y, Saeki T, Kawada K, Igarashi T, Usubuchi N, Ueda R, Sasaki Y, Minami H (2005) Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5′-deoxy-5-fluorouridine (5′-DFUR). Cancer Chemother Pharmacol 56:205–211
Ohno S, Mitsuyama S, Tamura K, Nishimura R, Tanaka M, Hamada Y, Kuroki S, Kyushu Breast Cancer Study Group (2007) Dosage of capecitabine and cyclophosphamide combination therapy in patients with metastatic breast cancer. Anticancer Res 27:1009–1013
Common Terminology Criteria for Adverse Events (CTCAE v3.0) (2004) 2003 (Japanese translation JCOG/JCSP version, 2004) Int J Clin Oncol 9(Suppl III):1–82 (in Japanese)
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
Kusama M, Nomizu T, Aogi K, Yoshimoto M, Horikoshi N, Tabei T, Noguchi S, Miura S, Yoshimura N, Kimura M, Toyama K, Shin E (2010) Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer. Breast Cancer 17:233–240
Banna GL, Simonelli M, Santoro A (2007) High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation for the treatment of solid tumors in adults: a critical review. Curr Stem Cell Res Ther 2:65–82
Epstein RJ (1999) Drug-induced DNA damage and tumor chemosensitivity. J Clin Oncol 8:2062–2084
Goss PE, Chambers AF (2010) Does tumour dormancy offer a therapeutic target? Nat Rev Cancer 10:871–877
O’Shaughnessy J (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10:20–29
Tanaka Y, Eda H, Fujimoto K, Tanaka T, Ishikawa T, Ishitsuka H (1990) Anticachectic activity of 5′-deoxy-5-fluorouridine in a murine tumor cachexia model, colon 26 adenocarcinoma. Cancer Res 50:4528–4532
Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, Belau A, Khandan F, Hauschild M, Thomssen C, Högel B, Darb-Esfahani S, Mehta K, Loibl S (2010) Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 124:133–140
Hall C, Krishnamurthy S, Lodhi A, Mosalpuria K, Kuerer HM, Meric-Bernstam F, Bedrosian I, Hunt KK, Lucci A (2010) Disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients. Ann Surg Oncol 17:3252–3259
Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, Kusama M, Yamazaki K, Hisamatsu K, Sato Y, Kashiwaba M, Kaise H, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Takatsuka Y, Japan Breast Cancer Research Group (JBCRG) (2008) Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat 110:531–539
Albain KS, Paik S, van’t Veer L (2009) Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast 18(Suppl 3):S141–S145
Piccart MJ (1999) Integration of new therapies into management of metastatic breast cancer: a focus on chemotherapy, treatment selection through use of molecular markers, and newly developed biologic therapies in late clinical development. ASCO Educ Book, pp 526–539
Acknowledgments
The authors wish to thank the participating patients and their families, and the clinical trial investigators. This clinical study was supported by the non-profit organization ECRIN (Epidemiological and Clinical Research Information Network, Kyoto, Japan).
Conflict of interest
There was no financial disclosure from any of the authors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yoshimoto, M., Takao, S., Hirata, M. et al. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer. Cancer Chemother Pharmacol 70, 331–338 (2012). https://doi.org/10.1007/s00280-012-1826-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-012-1826-x